Filing Details

Accession Number:
0001415889-15-000153
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-01-15 18:03:46
Reporting Period:
2015-01-13
Filing Date:
2015-01-15
Accepted Time:
2015-01-15 18:03:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1291881 Torsten Rasmussen 11085 Torreyana Road #100
San Diego CA 92121
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-01-13 4,685 $15.02 13,185 No 4 M Indirect See footnote
Common Stock Acquisiton 2015-01-13 7,220 $8.49 20,405 No 4 M Indirect See footnote
Common Stock Disposition 2015-01-13 11,905 $35.00 8,500 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect See footnote
No 4 M Indirect See footnote
No 4 S Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2015-01-13 4,685 $0.00 4,685 $15.02
Common Stock Stock option (right to buy) Disposition 2015-01-13 7,220 $0.00 7,220 $8.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2017-06-14 No 4 M Indirect
2,780 2018-06-12 No 4 M Indirect
Footnotes
  1. Shares and options are held by Morgan Management Aps, a Danish corporation in which Mr. Rasmussen has a controlling interest.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2014.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.01 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
  4. 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 15, 2007.
  5. 25% of the share subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008.